Terms: = Breast cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
37 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
3. GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model.
Hernández-Aceves JA; Cervantes-Torres J; Torres-García D; Zuñiga-Flores FJ; Patiño-Chávez OJ; Peña Agudelo JA; Aguayo-Flores JE; Garfias Y; Montero-León L; Romero-Romero L; Pérez-Torres A; Fragoso G; Sciutto E
Cancer Immunol Immunother; 2023 Nov; 72(11):3825-3838. PubMed ID: 37736849
[TBL] [Abstract] [Full Text] [Related]
4. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
5. High PD-L2 Predicts Early Recurrence of ER-Positive breast cancer.
Chervoneva I; Peck AR; Sun Y; Yi M; Udhane SS; Langenheim JF; Girondo MA; Jorns JM; Chaudhary LN; Kamaraju S; Bergom C; Flister MJ; Hooke JA; Kovatich AJ; Shriver CD; Hu H; Palazzo JP; Bibbo M; Hyslop T; Nevalainen MT; Pestell RG; Fuchs SY; Mitchell EP; Rui H
JCO Precis Oncol; 2023 Jan; 7():e2100498. PubMed ID: 36652667
[TBL] [Abstract] [Full Text] [Related]
6. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract] [Full Text] [Related]
7. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable clinical outcomes in Triple-Negative breast cancer.
Shinohara H; Kobayashi M; Hayashi K; Nogawa D; Asakawa A; Ohata Y; Kubota K; Takahashi H; Yamada M; Tokunaga M; Kinugasa Y; Oda G; Nakagawa T; Onishi I; Kinowaki Y; Kurata M; Ohashi K; Kitagawa M; Yamamoto K
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362023
[TBL] [Abstract] [Full Text] [Related]
8. Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X; Qin P; Wang Y; Zhang M; Cui H; Gao Q; Wang Z
Cancer Immunol Immunother; 2023 Feb; 72(2):385-395. PubMed ID: 35907016
[TBL] [Abstract] [Full Text] [Related]
9. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract] [Full Text] [Related]
10. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update.
Brown LC; Loi S
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S29-S33. PubMed ID: 34996667
[TBL] [Abstract] [Full Text] [Related]
11. Effect of Primary Systemic Therapy on pd-1, PD-L1, and PD-L2 mRNA Expression in Advanced breast cancer.
Karsono R; Azhar MA; Pratiwi Y; Saputra F; Nadliroh S; Aryandono T
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2069-2077. PubMed ID: 34319029
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
[TBL] [Abstract] [Full Text] [Related]
13. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
[TBL] [Abstract] [Full Text] [Related]
14. A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
Lecchi M; Verderio P; Cappelletti V; De Santis F; Paolini B; Monica M; Sangaletti S; Pupa SM; Iorio MV; Bianchi G; Gennaro M; Fucà G; De Braud F; Tagliabue E; Di Nicola M
Mol Oncol; 2021 May; 15(5):1345-1357. PubMed ID: 33523584
[TBL] [Abstract] [Full Text] [Related]
15. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract] [Full Text] [Related]
16. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
[TBL] [Abstract] [Full Text] [Related]
18. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract] [Full Text] [Related]
19. Molecular stratification within triple-negative breast cancer subtypes.
Wang DY; Jiang Z; Ben-David Y; Woodgett JR; Zacksenhaus E
Sci Rep; 2019 Dec; 9(1):19107. PubMed ID: 31836816
[TBL] [Abstract] [Full Text] [Related]
20. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-pd-1/PD-L1 Therapeutic Efficacy.
Lee HH; Wang YN; Xia W; Chen CH; Rau KM; Ye L; Wei Y; Chou CK; Wang SC; Yan M; Tu CY; Hsia TC; Chiang SF; Chao KSC; Wistuba II; Hsu JL; Hortobagyi GN; Hung MC
Cancer Cell; 2019 Aug; 36(2):168-178.e4. PubMed ID: 31327656
[TBL] [Abstract] [Full Text] [Related]
[Next]
